MAIA Biotechnology
Coming April 18, 2023

New Drug Platform Kills Up To 90% Of Cancer Cells In Under 72 Hours

Date & Time


April 18, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval

About the Event


MAIA Biotechnology (NYSE: MAIA) has developed THIO, a new platform of telomere-targeting agents that attack cancer tumors in a whole new way. It kills 70-90% of the cancer cells in just 24-72 hours and when used with a checkpoint inhibitor leads to complete response and no recurrence.

The company recently announced positive topline data from the completed Part A safety lead-in of their THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection.

Join our webinar with MAIA CEO, Vlad Vitoc, to hear about the company’s Phase 2 clinical trials and why the FDA has awarded the platform two Orphan Drug Designations.

Sign Up Today


SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.